Metabolic syndrome resolution by Roux-en-Y gastric bypass in a real world: a case control study

Abstract

Metabolic syndroMe resolution by roux-en-y gastric bypass in a real world: a case control study rev assoC med bras 2015; 61 (2) Conflict of interest: noneObjectives: the aim of this study was to evaluate the efficacy of Roux-en-Y Gastric Bypass (RYGB), compared with nonsurgical treatment (NS group), as an instrument for inducing remission of co-morbidities related to Metabolic Syndrome (MetS) in patients with Obesity, grades 2 and 3 (Ob2,3). Methods: two hundred and fifty eight Ob2,3 patients were selected in a retrospective analysis and included in a case control study. MetS was defined as described by the International Diabetes Federation. One hundred and twenty-nine of these patients underwent RYGB (S group), and 129 were assessed as an NS group. Results: at baseline, S and NS groups did not differ in BMI, age, female sex and prevalence of MetS (p>0.05). For the S group the outcomes were a reduction in BMI of 38.1% (p<0.001), waist circumference of 28.6% (p<0.001), fasting plasma glucose of 10.5% (p<0.001), serum LDL-cholesterol of 21.9% (p<0.001) and of 85% in the number of patients with MetS (p<0.001). For the NS group, only a decrease of 4.12%(p=0.047) in triglyceride levels and of 5.9%(p=0.031) in Diastolic Blood Pressure was observed. In the NS group, 98.6% of the patients continued to have MetS. The number needed to treat (NNT) with surgery to resolve one case of MetS was 1.2 (CI 95%: 1.1 -1.4). Conclusion: in the real world, in the South of Brazil, compared with NS treatment and after 1 year of observation, RYGB is highly effective for decreasing the prevalence of MetS.

Evaluación de los parámetros del síndrome metabólico después del bypass gástrico Roux-y

“…De los diez estudios seleccionados, todos tenían como objetivo verificar la influencia de la cirugía bariátrica en los parámetros del síndrome metabólico, dos de ellos analizaron la regularidad de la resistencia a la insulina por la Homeostasis Model Assessment (HOMA), y se evaluó el proceso inflamatorio en comparación con el nivel de seum de C-Reactive Protein, así como las enzimas hepáticas (JIMÉNEZ, 2013;IANELLI, 2013). Además, dos estudios incluyeron análisis y calidad de vida (AFTAB et al, 2014), y la resolución de comorbilidades no metabólicas asociadas con la obesidad (SCHMID et al, 2015).…”

“…En cuanto al diseño del estudio, un análisis retrospectivo y una colección prospectiva Evaluación de los parámetros del síndrome metabólico después del bypass gástrico Roux-y www.nucleodoconhecimento.com.br (JIMÉNEZ, 2013), dos estudios de caso-control (IANNELLI et al, 2013;SCHMID et al, 2015) y siete estudios de cohortes (AFTAB et al, 2014;FARIA et al, 2014;JUNGES et al, 2017;MONTEIRO et al, 2009;ORTIZ et al, 2015;RAMOS et al, 2016;SILVA et al, 2013).…”

Peripheral polyneuropathy in severely obese patients with metabolic syndrome but without diabetes: Association with low HDL-cholesterol

“…22 Thus, the main recommendation made to increase HDL-cholesterol is physical exercise. [23][24][25] Since a study conducted by our research group showed that 1 year of Roux-en-Y gastric bypass decreased serum levels of blood glucose, total cholesterol, LDL-cholesterol and triglycerides, but did not improve HDL cholesterol, 26 it is also possible that PPN described after this kind of bariatric surgery by other authors 27 could be related to the low HDL-cholesterol levels that these sedentary patients usually present, as well as to vitamin deficiency.…”

Bewertung der Parameter des metabolischen Syndroms nach dem Roux-y Magenbypass

“…Mortalität zeigt sich in 45 % der Fälle von DM2 und in 25 % der Fälle von Herz-Kreislauf-Erkrankungen (Hruby et al, 2015 -Kontroll-Studien (IANNELLI et al, 2013;SCHMID et al, 2015) und sieben Kohortenstudien (AFTAB et al, 2014FARIA et al, 2014;JUNGES et al, 2017;MONTEIRO et al, 2009;ORTIZ et al, 2015;RAMOS et al, 2016;SILVA et al, 2013).…”